This inventor holds 43 USPTO granted patents, primarily in Oligonucleotide Therapies. Top assignees: Ribozyme Pharmaceuticals, Incorporated, Isis Pharmaceuticals, Inc., Other. Active years: 1993-2003.
Location History:
- Richmond, OH (US) (1997)
- San Marcos, CA (US) (1993 - 2001)
- Solon, OH (US) (1997 - 2001)
- Boulder, CO (US) (1995 - 2003)
Company Filing History:
33 out of 110Â 
9 out of 1,035Â 
1 out of 834,411Â Years Active: 1993-2003
Areas of Expertise:
Title: Innovations and Contributions of Kenneth G. Draper
Introduction
Kenneth G. Draper is a prominent inventor based in Boulder, CO, recognized for his significant contributions to the field of biotechnology. With an impressive portfolio of 43 patents, Draper has focused on innovative methods for treating various cancers through the manipulation of gene expression.
Latest Patents
Among his latest patents, Draper has developed a method and reagent for the treatment of diseases by the expression of the c-Myc gene. This innovation involves an enzymatic RNA molecule that cleaves mRNA associated with the development or maintenance of Burkitt's lymphoma or acute lymphocytic leukemia. Additionally, he has patented a method and reagent for the treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression, also utilizing an enzymatic RNA molecule to target mRNA related to lung cancer.
Career Highlights
Throughout his career, Kenneth G. Draper has made significant strides in the biotech sector. He has held key roles at leading companies, including Ribozyme Pharmaceuticals, Incorporated and Isis Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in therapeutic RNA technologies.
Collaborations
Draper's innovative work has not only been influenced by his own research but also through collaboration with esteemed colleagues such as James A. McSwiggen and Dan T. Stinchcomb. These partnerships have greatly contributed to the evolution of his groundbreaking projects in cancer treatment and gene therapy.
Conclusion
Kenneth G. Draperk continues to be a leading figure in the field of biotechnology, with a clear commitment to addressing complex medical challenges through innovative inventions. His patents and collaborations reflect a deep understanding of cancer biology, positioning him as a valuable contributor to the advancement of medical science.